Dr Freeman on Factors Influencing Response to CAR T-Cell Therapy in Hematology
Ciara Freeman, MD, PhD, discusses findings from a longitudinal single-cell analysis that was conducted to pinpoint factors linked to either a positive response or therapeutic failure with FDA-approved, BCMA-directed CAR T-cell therapy in patients with hematologic malignancies.
Ciara Freeman Moffitt Cancer Institution Cellular Immunotherapy Program Moffitt Cancer Center Medical Oncology Marrow Transplant
Source: onclive.com